Loss of dihydroceramide desaturase drives neurodegeneration by disrupting endoplasmic reticulum and lipid droplet homeostasis in glial cells

Reviewer #1 (Public Review):
Summary:

Zhu et al., investigate the cellular defects in glia as a result of loss in DEGS1/ifc encoding the dihydroceramide desaturase. Using the strength of Drosophila and its vast genetic toolkit, they find that DEGS1/ifc is mainly expressed in glia and its loss leads to profound neurodegeneration. This supports a role for DEGS1 in the developing larval brain as it safeguards proper CNS development. Loss of DEGS1/ifc leads to dihydroceramide accumulation in the CNS and induces alteration in the morphology of glial subtypes and a reduction in glial number. Cortex and ensheathing glia appeared swollen and accumulated internal membranes. Astrocyte-glia on the other hand displayed small cell bodies, reduced membrane extension and disrupted organization in the dorsal ventral nerve cord. They also found that DEGS1/ifc localizes primarily to the ER. Interestingly, the authors observed that loss of DEGS1/ifc drives ER expansion and reduced TGs and lipid droplet numbers. No effect on PC and PE and a slight increase in PS.

The conclusions of this paper are well supported by the data. The study could be further strengthened by a few additional controls and/or analyses.

Strengths:

This is an interesting study that provides new insight into the role of ceramide metabolism in neurodegeneration.

The strength of the paper is the generation of LOF lines, the insertion of transgenes and the use of the UAS-GAL4/GAL80 system to assess the cell-autonomous effect of DEGS1/ifc loss in neurons and different glial subtypes during CNS development.

The imaging, immunofluorescence staining and EM of the larval brain and the use of the optical lobe and the nerve cord as a readout are very robust and nicely done.

Drosophila is a difficult model to perform core biochemistry and lipidomics but the authors used the whole larvae and CNS to uncover global changes in mRNA levels related to lipogenesis and the unfolded protein responses as well as specific lipid alterations upon DEGS1/ifc loss.

Weaknesses:

The authors performed lipidomics and RTqPCR on whole larvae and larval CNS from which it is impossible to define the cell type-specific effects. Ideally, this could be further supported by performing single cell RNAseq on larval brains to tease apart the cell-type specific effect of DEGS1/ifc loss.

It's clear from the data that the accumulation of dihydroceramide in the ER triggers ER expansion but it remains unclear how or why this happens. Additionally, the authors assume that, because of the reduction in LD numbers, that the source of fatty acids comes from the LDs. But there is no data testing this directly.

The authors performed a beautiful EMS screen identifying several LOF alleles in ifc. However, the authors decided to only use KO/ifcJS3. The paper could be strengthened if the authors could replicate some of the key findings in additional fly lines.

The authors use M{3xP3-RFP.attP}ZH-51D transgene as a general glial marker. However, it would be advised to show the % overlap between the glial marker and the RFP since a lot of cells are green positive but not perse RFP positive and vice versa.

The authors indicate that other 3xP3 RFP and GFP transgenes at other genomic locations also label most glia in the CNE. Do they have a preferential overlap with the different glial subtypes?

Reviewer #2 (Public Review):

Summary:
The manuscript by Zhu et al. describes phenotypes associated with the loss of the gene ifc using a Drosophila model. The authors suggest their findings are relevant to understanding the molecular underpinnings of a neurodegenerative disorder, HLD-18, which is caused by mutations in the human ortholog of ifc, DEGS1.
The work begins with the authors describing the role for ifc during fly larval brain development, demonstrating its function in regulating developmental timing, brain size, and ventral nerve cord elongation. Further mechanistic examination revealed that loss of ifc leads to depleted cellular ceramide levels as well as dihydroceramide accumulation, eventually causing defects in ER morphology and function. Importantly, the authors showed that ifc is predominantly expressed in glia and is critical for maintaining appropriate glial cell numbers and morphology. Many of the key phenotypes caused by the loss of fly ifc can be rescued by overexpression of human DEGS1 in glia, demonstrating the conserved nature of these proteins as well as the pathways they regulate. Interestingly, the authors discovered that the loss of lipid droplet formation in ifc mutant larvae within the cortex glia, presumably driving the deficits in glial wrapping around axons and subsequent neurodegeneration, potentially shedding light on mechanisms of HLD-18 and related disorders.

Strengths:
Overall, the manuscript is thorough in its analysis of ifc function and mechanism. The data images are high quality, the experiments are well controlled, and the writing is clear.

Weaknesses:
(1) The authors clearly demonstrated a reduction in number of glia in the larval brains of ifc mutant flies. What remains unclear is whether ifc loss leads to glial apoptosis or a failure for glia to proliferate during development. The authors should distinguish between these two hypotheses using apoptotic markers and cell proliferation markers in glia.

(2) It is surprising that human DEGS1 expression in glia rescues the noted phenotypes despite the different preference for sphingoid backbone between flies and mammals. Though human DEGS1 rescued the glial phenotypes described, can animal lethality be rescued by glial expression of human DEGS1? Are there longer-term effects of loss of ifc that cannot be compensated by the overexpression of human DEGS1 in glia (age-dependent neurodegeneration, etc.)?

(3) The mechanistic link between the loss of ifc and lipid droplet defects is missing. How do defects in ceramide metabolism alter triglyceride utilization and storage? While the author's argument that the loss of lipid droplets in larval glia will lead to defects in neuronal ensheathment, a discussion of how this is linked to ceramides needs to be added.

(4) On page 10, the authors use the words "strong" and "weak" to describe where ifc is expressed. Since the use of T2A-GAL4 alleles in examining gene expression is unable to delineate the amount of gene expression from a locus, the terms "broad" and "sparse" labeling (or similar terms) should be used instead.

Reviewer #3 (Public Review):

Summary:
In this manuscript, the authors report three novel ifc alleles: ifc[js1], ifc[js2], and ifc[js3]. ifc[js1] and ifc[js2] encode missense mutations, V276D and G257S, respectively. ifc[js3] encodes a nonsense mutation, W162*. These alleles exhibit multiple phenotypes, including delayed progression to the late-third larval instar stage, reduced brain size, elongation of the ventral nerve cord, axonal swelling, and lethality during late larval or early pupal stages.
Further characterization of these alleles the authors reveals that ifc is predominantly expressed in glia and localizes to the endoplasmic reticulum (ER). The expression of ifc gene governs glial morphology and survival. Expression of fly ifc cDNA or human DEGS1 cDNA specifically in glia, but not neurons, rescues the CNS phenotypes of ifc mutants, indicating a crucial role for ifc in glial cells and its evolutionary conservation. Loss of ifc results in ER expansion and loss of lipid droplets in cortex glia. Additionally, loss of ifc leads to ceramide depletion and accumulation of dihydroceramide. Moreover, it increases the saturation levels of triacylglycerols and membrane phospholipids. Finally, the reduction of dihydroceramide synthesis suppresses the CNS phenotypes associated with ifc mutations, indicating the key role of dihydroceramide in causing ifc LOF defects.

Strengths:
This manuscript unveils several intriguing and novel phenotypes of ifc loss-of-function in glia. The experiments are meticulously planned and executed, with the data strongly supporting their conclusions.

Weaknesses:
I didn't find any obvious weakness.

Author response:

'We thank the reviewers for their helpful comments and criticisms of our manuscript and are pleased by the overall positive nature of the comments. For the eLife Version of Record, we plan to carry out the following experiments to address reviewer comments:

- We will use genetic approaches (e.g., driving p35 in glia to block apoptosis) and molecular markers, such as phospho-Histone H3, to assess whether reduced glial proliferation or increased glial apoptosis contributes to reduced glial cell number.

- We will assess the ability of glial-specific expression of the Drosophila or Human ifc/DEGS1 transgenes to rescue the ifc lethal phenotype to adulthood.

- We will replicate key phenotypic findings with additional ifc alleles.

- We will enhance our characterization of 3xP3 RFP transgenes with respect to glial subtypes both for the insert we used in our study and at least one independent insert.

- We will edit the text of the manuscript to clarify additional points raised by the reviewers.

Once we complete the above approaches, we will modify our manuscript accordingly and submit a full response to the reviews to eLife along with the revised manuscript,'